Searchable abstracts of presentations at key conferences in endocrinology

ea0086p105 | Neuroendocrinology and Pituitary | SFEBES2022

Case Series: Primary / neo-adjuvant 131I-MIBG therapy as a safe and effect treatment in the management of pheochromocytoma / paraganglioma

Onyema Michael , Crane James , Reynolds Saira , Whitelaw Benjamin

Background: As per 2014 Endocrine Society guidelines, 131I-MIBG therapy is usually reserved for metastatic or unresectable disease in patients with pheochromocytoma / paraganglioma. In this series, we describe three patients effectively treated with primary 131I-MIBG therapy. The indications were primary neo-adjuvant therapy prior to surgery, or palliative.Case series: Case 1 – 18-year-old male with a 60 mm para-aortic paragang...

ea0094op7.4 | RET and Endocrine Cancer | SFEBES2023

Primary ovarian failure after 131I-metaiodobenzylguanide (MIBG) therapy

Dhar Mili , Crane James , Heraghty Neil , Reynolds Saira

131I-metaiodobenzylguanide (MIBG) therapy, initially introduced in the 1980s, has emerged as a first-line to treatment of malignant phaeochromocytomas. Its other notable use has been in treating neuroblastomas occurring in childhood serving as an adjuvant prior to surgery or chemotherapy. An observed known late consequence of MIBG therapy is Primary ovarian failure (POI), characterised by menstrual irregularities over a period of 4 months associated with high Follicular stimul...

ea0086p194 | Endocrine Cancer and Late Effects | SFEBES2022

The incidence and clinical significance of metabolically active brown adipose tissue in patients with pheochromocytomas and paragangliomas: A retrospective cohort study, systematic review and meta-analysis

Onyema Michael , Ostarijas Eduard , Minhas Raisa , Roy Aparajita , Kearney Jessica , Omran Asma , Zair Zoulikha , Reynolds Saira , Mulholland Nicola , Corcoran Benjamin , Halim Mohammad , Aylwin Simon , Dimitriadis Georgios K

There is limited research into the impact of active brown adipose tissue (aBAT) in patients with phaeochromocytomas and paragangliomas (PPGLs). A small body of evidence has shown that patients with PPGL patients can exhibit a high prevalence for aBAT recognized as ranging between 8 - 28% without specific correlation to germline mutations. Furthermore, it has been suggested that aBAT may be linked to increased mortality. Systematic searches of the Medical Literature Analysis an...